Blog

/Blog

FDA approves Darzalex® for patients with previously treated multiple myeloma

On November 16th, 2016 the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex® (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex® is the first [...]

December 13th, 2016|Blog, News|

Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth

Diabetes mellitus characterized by hyperglycemia is an increasing worldwide health problem. It is largely classified into insulin-dependent diabetes mellitus (type 1 diabetes) and noninsulin-dependent diabetes mellitus (type 2 diabetes). The type 2 diabetes (T2D) makes [...]

December 7th, 2016|Blog, News|

FDA Approves Prasterone (Intrarosa®) for Dyspareunia in Postmenopausal Women

On November 17th, 2016 the U.S. Food and Drug Administration (FDA) approved Intrarosa® (prasterone) manufactured by Quebec-based Endoceutics Inc.to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and [...]

December 5th, 2016|Blog, News|

Direct Switching From TNF Rheumatoid Arthritis (RA) Drugs Shows Beneficial Effect in Non-Responsive Patients

Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by persistent synovitis and systemic inflammation. Genetic predisposition as well as autoantibodies and environmental factors, such as smoking, are associated with an increased risk of [...]

November 21st, 2016|Blog, Pharmacy|

Antibiotic restores cell communication in brain areas damaged by Alzheimer’s-like disease in mice

New research from the Djavad Mowafaghian Centre for Brain Health at the University of British Columbia (UBC) has found a way to partially restore brain cell communication around areas damaged by plaques associated with Alzheimer's [...]

November 21st, 2016|Blog, Science|

FDA Strengthens Warnings for All Testosterone Containing Products: Risk of Heart Attack and Stroke Associated With Use

The Food and Drug Administration (FDA) has just approved class-wide labeling changes for all prescription testosterone products to inform of possible increased risk of heart attack and stroke with use, the agency announced today1-3. The [...]

November 10th, 2016|Blog, News|